Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
Jaguar Health (NASDAQ:JAGX) announced positive proof-of-concept results for their drug crofelemer in treating a third intestinal failure patient. The novel liquid formulation demonstrated efficacy in reducing total parenteral nutrition (TPN) requirements in a second pediatric patient with short bowel syndrome (SBS-IF).
The results build on previously reported data showing crofelemer reduced TPN requirements by up to 27% in microvillus inclusion disease (MVID) patients and up to 12.5% in SBS-IF patients. Notably, when the first two patients were taken off crofelemer after 12 weeks of treatment, their symptoms worsened, leading to prompt reinstatement of the treatment.
The company is conducting multiple studies, including two independent proof-of-concept investigator-initiated trials (IITs) and two placebo-controlled Phase 2 studies. The Phase 2 study in pediatric MVID patients is expected to complete by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize their intestinal failure products, aiming to generate non-dilutive funding.
[ "Crofelemer reduced TPN requirements by up to 27% in MVID patients and 12.5% in SBS-IF patients", "Second pediatric SBS-IF patient showed similar positive response for TPN reduction", "No safety issues reported at highest protocol-approved dose", "Results may support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program", "Data could support reimbursed early patient access in EU countries" ]Jaguar Health (NASDAQ:JAGX) ha annunciato risultati positivi di proof-of-concept per il loro farmaco crofelemer nel trattamento di un terzo paziente con insufficienza intestinale. La nuova formulazione liquida ha dimostrato efficacia nel ridurre le necessit脿 di nutrizione parenterale totale (TPN) in un secondo paziente pediatrico con sindrome da intestino corto (SBS-IF).
I risultati si basano su dati precedenti che mostrano come il crofelemer abbia ridotto le necessit脿 di TPN fino al 27% nei pazienti con malattia da inclusione dei microvilli (MVID) e fino al 12,5% nei pazienti con SBS-IF. 脠 importante notare che, quando i primi due pazienti sono stati sospesi dal trattamento con crofelemer dopo 12 settimane, i loro sintomi sono peggiorati, portando alla pronta ripresa della terapia.
L鈥檃zienda sta conducendo diversi studi, inclusi due trial indipendenti di proof-of-concept avviati da ricercatori (IIT) e due studi di Fase 2 controllati con placebo. Lo studio di Fase 2 su pazienti pediatrici con MVID dovrebbe concludersi entro la met脿 del 2026. Jaguar 猫 attivamente alla ricerca di partnership di sviluppo commerciale per ottenere diritti di licenza per sviluppare e commercializzare i propri prodotti per l鈥檌nsufficienza intestinale, con l鈥檕biettivo di generare finanziamenti non diluitivi.
- Il crofelemer ha ridotto le necessit脿 di TPN fino al 27% nei pazienti MVID e al 12,5% nei pazienti SBS-IF
- Il secondo paziente pediatrico con SBS-IF ha mostrato una risposta positiva simile nella riduzione della TPN
- Non sono stati segnalati problemi di sicurezza alla dose pi霉 alta approvata dal protocollo
- I risultati potrebbero supportare l鈥檌nclusione nel programma PRIME dell鈥橢MA e nel programma Breakthrough Therapy della FDA
- I dati potrebbero favorire l鈥檃ccesso precoce rimborsato per i pazienti nei paesi UE
Jaguar Health (NASDAQ:JAGX) anunci贸 resultados positivos de prueba de concepto para su medicamento crofelemer en el tratamiento de un tercer paciente con insuficiencia intestinal. La novedosa formulaci贸n l铆quida demostr贸 eficacia en la reducci贸n de los requerimientos de nutrici贸n parenteral total (TPN) en un segundo paciente pedi谩trico con s铆ndrome de intestino corto (SBS-IF).
Los resultados se basan en datos previos que mostraron que crofelemer redujo los requerimientos de TPN hasta en un 27% en pacientes con enfermedad de inclusi贸n de microvellosidades (MVID) y hasta un 12,5% en pacientes con SBS-IF. Es importante destacar que, cuando los dos primeros pacientes dejaron de recibir crofelemer tras 12 semanas de tratamiento, sus s铆ntomas empeoraron, lo que llev贸 a la pronta reinstauraci贸n del tratamiento.
La compa帽铆a est谩 realizando m煤ltiples estudios, incluyendo dos ensayos independientes de prueba de concepto iniciados por investigadores (IIT) y dos estudios controlados con placebo de Fase 2. Se espera que el estudio de Fase 2 en pacientes pedi谩tricos con MVID finalice para mediados de 2026. Jaguar est谩 activamente buscando asociaciones de desarrollo comercial para obtener derechos de licencia para desarrollar y comercializar sus productos para insuficiencia intestinal, con el objetivo de generar financiamiento no dilutivo.
- Crofelemer redujo los requerimientos de TPN hasta en un 27% en pacientes con MVID y un 12,5% en pacientes con SBS-IF
- El segundo paciente pedi谩trico con SBS-IF mostr贸 una respuesta positiva similar en la reducci贸n de TPN
- No se reportaron problemas de seguridad en la dosis m谩s alta aprobada por el protocolo
- Los resultados podr铆an apoyar la inclusi贸n en el programa PRIME de la EMA y en el programa Breakthrough Therapy de la FDA
- Los datos podr铆an respaldar el acceso temprano reembolsado para pacientes en pa铆ses de la UE
Jaguar Health (NASDAQ:JAGX)電� 靹� 氩堨Ц 鞛� 旮半姤 攵�鞝� 頇橃瀽 旃橂鞐� 鞛堨柎 鞎诫 韥韼犽煬毹胳潣 旮嶌爼鞝侅澑 臧滊厫 歃濍獏 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 靸堧鞖� 鞎§儊 鞝滍槙鞚� 雼灔 歃濏泟甑�(SBS-IF)鞚� 臧�歆� 霊� 氩堨Ц 靻岇晞 頇橃瀽鞚� 齑� 牍勱步甑� 鞓侅枒(TPN) 鞖旉惮霟� 臧愳唽鞐� 須臣毳� 鞛呾頄堨姷雼堧嫟.
鞚� 瓴瓣臣電� 鞚挫爠鞐� 氤搓碃霅� 雿办澊韯办棎 旮半皹頃橂┌, 韥韼犽煬毹戈皜 氙胳劯鞙惦 韽暔 歆堩櫂(MVID) 頇橃瀽鞐愳劀 斓滊寑 27%, SBS-IF 頇橃瀽鞐愳劀 斓滊寑 12.5%旯岇 TPN 鞖旉惮霟夓潉 欷勳榾鞚岇潉 氤挫棳欷嶋媹雼�. 韸鬼瀳 斓滌磮 霊� 頇橃瀽臧� 12欤� 旃橂 頉� 韥韼犽煬毹� 韴棳毳� 欷戨嫧頄堨潉 霑� 歃濎儊鞚� 鞎呿檾霅橃柎 歃夑皝 旃橂臧� 鞛皽霅橃棃鞀惦媹雼�.
須岇偓電� 霊� 瓯挫潣 霃呺鞝侅澑 鞐瓣惮鞛� 欤茧弰 臧滊厫 歃濍獏 鞁滍棙(IIT)瓿� 霊� 瓯挫潣 鞙勳暯 雽�臁� 2靸� 鞐瓣惮毳� 韽暔頃� 雼れ垬鞚� 鞐瓣惮毳� 歆勴枆 欷戩瀰雼堧嫟. 靻岇晞 MVID 頇橃瀽 雽�靸� 2靸� 鞐瓣惮電� 2026雲� 欷戨皹 鞕勲霅� 鞓堨爼鞛呺媹雼�. Jaguar電� 鞛� 旮半姤 攵�鞝� 鞝滍拡鞚� 臧滊皽 氚� 靸侅毄頇旊ゼ 鞙勴暅 霛检澊靹犾姢 甓岆Μ毳� 頇曤炒頃橁赴 鞙勴暣 靷梾 臧滊皽 韺岉姼雱堨嫮鞚� 鞝侁饭 氇儔 欷戩澊氅�, 牍勴潿靹濎劚 鞛愱笀 臁半嫭鞚� 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
- 韥韼犽煬毹鸽姅 MVID 頇橃瀽鞐愳劀 斓滊寑 27%, SBS-IF 頇橃瀽鞐愳劀 12.5%旯岇 TPN 鞖旉惮霟夓潉 臧愳唽鞁滌及鞀惦媹雼�
- 霊� 氩堨Ц 靻岇晞 SBS-IF 頇橃瀽霃� 鞙犾偓頃� 旮嶌爼鞝� 氚橃潙鞚� 氤挫棳 TPN 臧愳唽鞐� 靹标车頄堨姷雼堧嫟
- 頂勲韱犾綔 鞀轨澑 斓滉碃 鞖╇焿鞐愳劀霃� 鞎堨爠靹� 氍胳牅 氤搓碃 鞐嗢潓
- 瓴瓣臣電� EMA鞚� PRIME 頂勲攴鸽灗 氚� FDA鞚� Breakthrough Therapy 頂勲攴鸽灗 韽暔鞚� 歆�鞗愴暊 靾� 鞛堨姷雼堧嫟
- 雿办澊韯半姅 EU 甑皜鞐愳劀 頇橃瀽鞚� 臁瓣赴 鞙犼笁 鞝戧芳鞚� 歆�鞗愴暊 靾� 鞛堨姷雼堧嫟
Jaguar Health (NASDAQ:JAGX) a annonc茅 des r茅sultats positifs de preuve de concept pour leur m茅dicament crofelemer dans le traitement d鈥檜n troisi猫me patient atteint d鈥檌nsuffisance intestinale. La nouvelle formulation liquide a d茅montr茅 son efficacit茅 en r茅duisant les besoins en nutrition parent茅rale totale (NPT) chez un deuxi猫me patient p茅diatrique souffrant du syndrome de l鈥檌ntestin court (SBS-IF).
Ces r茅sultats s鈥檃ppuient sur des donn茅es pr茅c茅demment rapport茅es montrant que le crofelemer r茅duisait les besoins en NPT jusqu鈥櫭� 27 % chez les patients atteints de maladie 脿 inclusion microvillositaire (MVID) et jusqu鈥櫭� 12,5 % chez les patients atteints de SBS-IF. Il est notable que, lorsque les deux premiers patients ont arr锚t茅 le crofelemer apr猫s 12 semaines de traitement, leurs sympt么mes se sont aggrav茅s, entra卯nant une reprise rapide du traitement.
L鈥檈ntreprise m猫ne plusieurs 茅tudes, dont deux essais ind茅pendants de preuve de concept initi茅s par des investigateurs (IIT) et deux 茅tudes de phase 2 contr么l茅es par placebo. L鈥櫭﹖ude de phase 2 chez les patients p茅diatriques atteints de MVID devrait se terminer d鈥檌ci mi-2026. Jaguar recherche activement des partenariats de d茅veloppement commercial pour obtenir les droits de licence afin de d茅velopper et commercialiser ses produits pour l鈥檌nsuffisance intestinale, dans le but de g茅n茅rer des financements non dilutifs.
- Le crofelemer a r茅duit les besoins en NPT jusqu鈥櫭� 27 % chez les patients MVID et 12,5 % chez les patients SBS-IF
- Le deuxi猫me patient p茅diatrique SBS-IF a montr茅 une r茅ponse positive similaire pour la r茅duction de la NPT
- Aucun probl猫me de s茅curit茅 signal茅 脿 la dose la plus 茅lev茅e approuv茅e par le protocole
- Les r茅sultats pourraient soutenir l鈥檌nclusion dans le programme PRIME de l鈥橢MA et le programme Breakthrough Therapy de la FDA
- Les donn茅es pourraient soutenir un acc猫s pr茅coce rembours茅 pour les patients dans les pays de l鈥橴E
Jaguar Health (NASDAQ:JAGX) gab positive Proof-of-Concept-Ergebnisse f眉r ihr Medikament Crofelemer bei der Behandlung eines dritten Patienten mit intestinalem Versagen bekannt. Die neuartige fl眉ssige Formulierung zeigte Wirksamkeit bei der Reduzierung des gesamten parenteralen Ern盲hrungsbedarfs (TPN) bei einem zweiten p盲diatrischen Patienten mit Kurzdarmsyndrom (SBS-IF).
Die Ergebnisse bauen auf zuvor ver枚ffentlichten Daten auf, die zeigten, dass Crofelemer den TPN-Bedarf bei Patienten mit Mikrovillus-Inklusionskrankheit (MVID) um bis zu 27% und bei SBS-IF-Patienten um bis zu 12,5% reduzierte. Bemerkenswert ist, dass sich die Symptome der ersten beiden Patienten verschlechterten, als sie nach 12 Wochen Behandlung von Crofelemer abgesetzt wurden, was zu einer schnellen Wiedereinsetzung der Therapie f眉hrte.
Das Unternehmen f眉hrt mehrere Studien durch, darunter zwei unabh盲ngige Proof-of-Concept-Investigator-initiierte Studien (IITs) und zwei placebokontrollierte Phase-2-Studien. Die Phase-2-Studie bei p盲diatrischen MVID-Patienten soll bis Mitte 2026 abgeschlossen sein. Jaguar sucht aktiv Gesch盲ftsentwicklungspartnerschaften zur Lizenzierung der Rechte zur Entwicklung und Vermarktung ihrer Produkte bei intestinalem Versagen, mit dem Ziel, nicht verw盲ssernde Finanzierung zu generieren.
- Crofelemer reduzierte den TPN-Bedarf bei MVID-Patienten um bis zu 27% und bei SBS-IF-Patienten um 12,5%
- Der zweite p盲diatrische SBS-IF-Patient zeigte eine 盲hnliche positive Reaktion bei der TPN-Reduktion
- Keine Sicherheitsprobleme bei der h枚chsten vom Protokoll genehmigten Dosis gemeldet
- Die Ergebnisse k枚nnten die Aufnahme in das PRIME-Programm der EMA und das Breakthrough-Therapy-Programm der FDA unterst眉tzen
- Daten k枚nnten eine erstattete fr眉hzeitige Patientenversorgung in EU-L盲ndern unterst眉tzen
- None.
- Patients' symptoms worsened when taken off crofelemer treatment
- Phase 2 study completion not expected until mid-2026
- Company seeking partnerships due to need for non-dilutive funding
Insights
Crofelemer shows promising TPN reduction in rare intestinal disorders, creating potential value for JAGX despite early-stage results.
Jaguar Health's press release highlights proof-of-concept results showing their drug crofelemer reduced total parenteral nutrition (TPN) requirements in a third intestinal failure patient - specifically a second pediatric patient with short bowel syndrome (SBS-IF). This follows previously reported reductions of
The clinical significance here is substantial. Both MVID and SBS-IF are rare intestinal failure conditions requiring long-term TPN, which carries serious complications including liver damage, infections, and cognitive deficits. Any therapy reducing TPN dependency addresses a critical unmet need.
Two compelling data points strengthen the evidence for crofelemer's effectiveness: First, patients who discontinued crofelemer after 12 weeks (per protocol) experienced symptom worsening and had to restart treatment prematurely. Second, even at the highest protocol-approved dose, no safety issues were reported in the SBS-IF patient.
The company is pursuing a strategic approach with these ultra-rare indications. Given MVID's extremely small patient population, even limited positive data might support expedited regulatory pathways through the EMA's PRIME program or FDA's Breakthrough Therapy designation. The company explicitly plans to leverage these preliminary results to seek business development partnerships and non-dilutive funding rather than pursuing costly later-stage trials independently.
While promising, it's important to recognize these are early results from a small, open-label, non-randomized investigator-initiated trial. The company's controlled Phase 2 studies won't complete until mid-2026. However, for ultra-rare diseases like MVID with no approved treatments, even limited positive evidence can potentially support accelerated approval pathways.
As recently , initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to
The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / / June 30, 2025 / () (Jaguar) family companies (Napo) and today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi.
As , and as presented April 26, 2025 at the , initial proof-of-concept results from this study show that crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, reduced the required TPN and supplementary intravenous fluids in the first participating MVID patient by up to
"We're very pleased to report that the second pediatric SBS-IF patient participating in this IIT exhibited a similar response for TPN reduction, further exemplifying that crofelemer's paradigm-shifting antisecretory mechanism of action may have the potential to provide a novel therapeutic option to modify disease progression due to the reductions in TPN and associated comorbidities in MVID and SBS-IF patients and improve their quality of life," said Lisa Conte, Jaguar's Founder and CEO. "This SBS-IF patient was administered the highest dose of crofelemer provided for in the approved protocol for the IIT, with no resulting safety issues."
Per the IIT protocol, as , the initial pediatric MVID patient participating in the study was taken off crofelemer after 12 weeks of treatment for an intended period of 30 days. However, after just 8 days, the patient's parents requested reinitiation of crofelemer dosing, as the patient's symptoms worsened - evidenced by increased stool output and decreased urine output - and the patient was restarted on daily treatment with crofelemer. The initial pediatric SBS-IF patient participating in the study also had crofelemer withdrawn per the protocol after 12 weeks. This patient then exhibited a relapse of symptoms and was put back on daily treatment with crofelemer, and has since been maintaining a significant TPN reduction. Jaguar plans to continue supplying crofelemer to Dr. Mohamad Miqdady, the principal investigator for this IIT, for the patients participating in this study for as long as Dr. Miqdady feels is medically necessary.
Dr. Miqdady has submitted initial proof-of-concept data from the ongoing IIT in Abu Dhabi for all three above-referenced patients to a major international pediatric gastroenterological conference for consideration for presentation.
Jaguar, through Jaguar family companies Napo and Napo Therapeutics, is currently supporting two independent proof-of-concept IITs, and conducting two placebo-controlled Phase 2 studies, of crofelemer in patients with intestinal failure due to MVID and SBS-IF in the United States, European Union, and/or Middle East/North Africa regions.
Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.
"Our strategy is to seek business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products - with the goal of generating non-dilutive funding for Jaguar," said Conte. "Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the ongoing IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval."
Based on the initial findings of the ongoing IIT in Abu Dhabi, crofelemer's paradigm-shifting antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in patients with intestinal failure due to MVID and short bowel syndrome. The observed groundbreaking TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN.
The initial proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) program that may accelerate regulatory approval pathways in the EU for this indication. This data may also support qualification of crofelemer for the FDA's program for expedited regulatory approval in the US. Additional proof-of-concept results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions.
The IIT in Abu Dhabi is being conducted by Dr. Miqdady at (SKMC), a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi. Dr. Miqdady, a recognized leader in pediatric gastroenterology, serves as the Chief of Pediatric Gastroenterology, Hepatology and Nutrition at SKMC. He is an American board-certified pediatric GI, hepatology and nutrition professor at in Abu Dhabi, and also serves as a member of Napo's Scientific Advisory Board. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit
Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit
Visit the Make Cancer Less Shitty patient advocacy program on , , &
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that completion of Napo's Phase 2 study of crofelemer in pediatric MVID patients will occur mid-2026, Jaguar's expectation that its strategy of seeking business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products may support generation of non-dilutive funding for Jaguar, Jaguar's expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval of crofelemer for MVID, Jaguar's expectation that crofelemer's mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar's expectation that proof-of-concept data in MVID may support crofelemer's potential inclusion in the EMA's PRIME program for expediated and assisted regulatory approval and in the FDA's Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar's expectation that additional proof-of-concept results from IITs will be available throughout 2025, and Jaguar's expectation that published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for MVID and SBS-IF. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original on ACCESS Newswire
FAQ
What were the key results of Jaguar Health's (JAGX) crofelemer trial in intestinal failure patients?
When will Jaguar Health complete its Phase 2 study for crofelemer in MVID patients?
What happened when patients stopped taking crofelemer in the trial?
What is Jaguar Health's business strategy for crofelemer?
What regulatory pathways is Jaguar Health pursuing for crofelemer?
